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Christian Benden, MD, Leah B. Edwards, PhD, Anna Y. Kucheryavaya, MS,
Jason D. Christie, MD, MS, Anne I. Dipchand, MD, FRCPC, Fabienne Dobbels, PhD,
Richard Kirk, MA, FRCP, FRCPCH, Lars H. Lund, MD, PhD, Axel O. Rahmel, MD,
Roger D. Yusen, MD, MPH, and Josef Stehlik, MD, MPH; for the International Society for
Heart and Lung TransplantationFrom the ISHLT Transplant Registry, Dallas, Texas.This section of the 16th official Registry report of the
International Society for Heart and Lung Transplantation
(ISHLT) summarizes the pediatric lung and heart-lung
transplantation activity from January 1986 through June
2012. Since 1986, 1,875 pediatric lung transplants and 667
pediatric heart-lung transplants have been reported. In 2011,
the last complete year included in this year’s Registry report,
107 pediatric lung transplants were performed, which is
comparable to figures in 2007 but lower than in 2010, when
125 procedures were performed.1 However, it is important
to note, that figures included in this Registry report contain
only the pediatric lung transplants that were reported to the
Registry and, thus, do not necessarily reflect numbers of
pediatric lung procedures performed worldwide.
This Registry report includes a summary of data analyses
performed by the Registry and is supplemented by further
analyses, Figures, and more detailed information available on
the ISHLT Web site (www.ishlt.org/registries). The 2013
Registry report on pediatric lung transplantation focuses for
the first time on an overall theme together with the Registry
reports on adult lung, adult heart, and pediatric heart
transplantation. The selected topic for this year’s reports is
age and age-related aspects of recipients and donors, along
with outcome-related analyses wherever sufficient data are
available. Data on pediatric heart-lung transplants are not
presented in this year’s report because those were presentedt matter Published by Elsevier Inc.
16/j.healun.2013.08.008
ef.stehlik@hsc.utah.edu
osef Stehlik, MD, MPH, University of Utah Health
ision of Cardiology, U.T.A.H. Cardiac Transplant
cal Dr, 4A100 SOM, Salt Lake City, UT 84132.
340. Fax: 801-581-7735.last year,1 and the number of heart-lung transplant procedures
in children and adolescents remains o 10 per year. In sum-
mary, this year’s Registry report on pediatric lung trans
plantation contains data on age and geographic distribution as
well as indications for pediatric lung transplantation, donor
characteristics, immunosuppressive therapy, outcome, com
plications, morbidities, and causes of death.Statistical methods
Survival rates were calculated by the Kaplan-Meier method
and compared with the log-rank test, and adjustments for
multiple comparisons were made using Scheffe’s method.
Survival graphs were truncated when the remaining number
of recipients was o 10. Multivariable analyses were done
using Cox proportional hazards models. Results of the
multivariable analyses were reported as hazard ratios (HR)
with a corresponding 95% confidence interval (CI) or
p-value. Multiple imputations were used to deal with
missing information for continuous data fields, as previously
described elsewhere.2 Additions to the statistical method-
ology are done on the supplement slides wherever
appropriate (www.ishlt.org/registries).Volume, age distribution, indications, and
donor characteristics
The number of pediatric lung transplants reported to the
Registry increased during the last decade, from 73 in 2000
to 107 in 2011, which is the last complete year included in
the Registry report. The highest numbers of reported
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Figure 2 Number of centers reporting pediatric lung trans-
plants by location.
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Figure 5 Donor age distribution (pediatric lung transplants:
January 1986–June 2012).
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Figure 1 Pediatric lung recipient age distribution by year of
transplant. ISHLT, International Society for Heart and Lung
Transplantation.
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Figure 4 Age distribution by location (pediatric lung trans-
plants: January 2000–June 2012).
The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013990pediatric lung transplants were performed in 2009 and 2010,
at 125 in both years (Figure 1). Similar to previous years,
most lung transplants were performed in older children
(aged 11–17 years). In 2011, 73% of children who received
a transplant were 11 years or older compared with 70% in
2010 (Figure 1). In contrast, only 3 infant lung transplants
(o 1 year) were reported in 2011.
The number of centers reporting pediatric lung trans-
plants to the Registry was almost equally divided between
European and North American centers (20 vs 18 in 2011),
whereas only 5 centers were located elsewhere (Figure 2). In0
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Figure 3 Number of centers reporting pediatric lung trans-
plants by center volume.2011, 43 centers worldwide performed lung transplants in
children, with 38 centers performing between 1 and 4 trans-
plant procedures per year, a volume distribution that has not
changed much over more than 2 decades. Only 2 centers
performed 10 to 19 lung transplants per year (Figure 3).
The regional age distribution of pediatric lung transplants
(Europe vs North America vs other countries) shows 84% of
lung transplant operations in Europe were performed in
older children (Z 11 years) compared with 68% in North
America (Figure 4). This pattern of geographic age
distribution also remained unchanged during recent years.0%
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Figure 6 Donor age distribution by location (pediatric lung
transplants: January 2000–June 2012).
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Figure 8 Diagnosis distribution by location (pediatric lung
transplants: January 2000–June 2012). IPAH, idiopathic pulmon-
ary arterial hypertension; IPF, idiopathic pulmonary fibrosis; OB,
obliterative bronchiolitis; Re-TX, retransplant.
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Figure 7 Diagnosis by year of transplant (lung transplant
recipients age: 11–17 years). IPAH, idiopathic pulmonary arterial
hypertension.
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Figure 10 Kaplan-Meier survival stratified by induction use
(pediatric lung transplants: January 2001–June 2011).
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Figure 11 Maintenance immunosuppression at time of follow-
up (pediatric lung transplants: January 2001–June 2012). MMF,
mycophenolate mofetil; MPA, mycophenolic acid.
Benden et al. ISHLT 16th Pediatric Lung and Heart-Lung Transplant Report 991The donor age distribution has remained similar
compared with previous years, with 63% of pediatric lung
transplant donors aged o 18 years (Figure 5). Only 6%
of donors wereZ 50 years, ando 1% of donors were aged
Z 60 years (Figure 5). Donor age distribution shows
substantial regional variation: in Europe, 43% of donors
were aged o 18 years, whereas in North America, 75% of
lung grafts came from donors aged o 18 years (Figure 6).0
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Figure 9 Induction immunosuppression (pediatric lung trans-
plants: January 2001–June 2012). ALG, anti-lymphocyte globulin;
ATG, anti-thymocyte globulin; IL, interleukin.In the last 2 decades, most pediatric patients required lung
transplant due to end-stage cystic fibrosis (CF) lung disease
(Figure 7). The frequency of diagnoses at the time of
transplants varies geographically: 54% of children with CF as
their diagnosis receive transplants in North America compared
with 73% in Europe (Figure 8). The distribution of transplant
indications is clearly age-dependent. In older children and
adolescents aged 11 to 17 years, about 70% receive
transplants for CF, whereas in children aged 6 to 10 years,
CF represents 53%. In the age group of 1 to 5 years old, theFigure 12 Maintenance immunosuppression drug combina-
tions at time of follow-up (pediatric lung recipients: January 2001–
June 2012). AZA, azathioprine; MMF, mycophenolate mofetil;
MPA, mycophenolic acid.
Table 1 Indications by Age Group (Pediatric Lung Transplants: January 1990–June 2012)
Diagnosis age group
o 1 year 1–5 years 6–10 years 11–17 years
Variable No. (%) No. (%) No. (%) No. (%)
Cystic fibrosis 1 (1.0) 6 (4.8) 140 (53.0) 916 (70.6)
Idiopathic pulmonary arterial hypertension 12 (12.5) 28 (22.4) 23 (8.7) 101 (7.8)
Retransplant
Obliterative bronchiolitis … 7 (5.6) 9 (3.4) 39 (3.0)
Not obliterative bronchiolitis 3 (3.1) 4 (3.2) 8 (3.0) 30 (2.3)
Congenital heart disease 16 (16.7) 10 (8.0) 4 (1.5) 11 (0.8)
Idiopathic pulmonary fibrosis 10 (10.4) 21 (16.8) 15 (5.7) 43 (3.3)
Obliterative bronchiolitis (not retransplant) … 10 (8.0) 18 (6.8) 55 (4.2)
Interstitial pneumonitis 1 (1.0) 2 (1.6) 2 (0.8) 1 (0.1)
Pulmonary vascular disease 8 (8.3) 7 (5.6) 4 (1.5) 1 (0.1)
Eisenmenger’s syndrome 1 (1.0) 5 (4.0) 3 (1.1) 9 (0.7)
Pulmonary fibrosis, other 7 (7.3) 11 (8.8) 14 (5.3) 29 (2.2)
Surfactant protein B deficiency 16 (16.7) 3 (2.4) … …
Chronic obstructive pulmonary disease/emphysema 4 (4.2) 2 (1.6) 2 (0.8) 10 (0.8)
Bronchopulmonary dysplasia 3 (3.1) 3 (2.4) 6 (2.3) 3 (0.2)
Bronchiectasis 1 (1.0) … 3 (1.1) 17 (1.3)
Other 13 (13.5) 6 (4.8) 13 (4.9) 32 (2.5)
The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013992leading diagnosis is idiopathic pulmonary arterial hyper-
tension (IPAH), with 22% of transplants (Table 1). In infants
(o 1 year), surfactant B deficiency, congenital heart disease,
and IPAH remain the 3 most frequent indications (Table 1).Immunosuppressive therapy
Induction
Sixty-two percent of recipients received induction therapy,
with most receiving an interleukin-2 (IL-2) receptor
antagonist, and only a minority receive anti-lymphocyte
globulin or anti-thymocyte globulin (Figure 9). As reported
in 2012,1 the number of pediatric lung transplant recipients
treated with an IL-2 receptor antagonist induction increased
in 2009 and stayed about the same since, but no significant
survival benefit was shown in a univariate analysis
comparing children who did and did not receive induction
therapy (Figure 10).Maintenance
Most commonly, pediatric lung transplant recipients
received a triple maintenance immunosuppressive treatment
of tacrolimus, mycophenolate mofetil/mycophenolic acid,
and prednisone. Tacrolimus was given to 83% of recipients
at 1 year after transplant and cyclosporine to 17% (patient
follow-up January 2001–June 2012; Figure 11). Mycophe-
nolate mofetil/mycophenolic acid remained the first choice
of cell-cycle inhibitor, used in 68% of children at 1 year
after transplantation. By 5 years, 9% of recipients received
a combination of tacrolimus plus sirolimus/everolimus
(Figure 12). As in the past,4 93% of children were treatedwith prednisone even 5 years after transplantation
(Figure 11).
Outcomes
Survival after pediatric lung transplantation is generally
comparable to that reported in adults (p ¼ 0.3459) with a
median survival of 4.9 years vs 5.4 years, respectively, in
recipients undergoing transplantation between January 1990
and June 2011 (Figure 13).
Primary transplants
As shown in previous reports, there was a significantly
better survival in children after bilateral/double-lung trans-
plants (n ¼ 1,553) compared with single-lung transplants
(n ¼ 94), with a median survival of 5.4 vs 1.9 years,
respectively (p o 0.0001; Figure 14). No significant
difference was seen when overall survival of 987 CF
recipients was compared with survival in 689 non-CF
recipients, with a median survival of 4.7 years in both
groups (Figure 15). Although based on absolute numbers,
the patient group that received transplants at age 6 to 10
years appeared to do better in the first several post-transplant
years, and none of the differences in survival among the age
groups were statistically significant (Figure 16). In recipi-
ents surviving past 1 year after transplantation, survival was
also similar among the different age groups (Figure 17).
Survival improved by era (1988–1999 vs 2000–June 2011),
with a median survival improving from 3.3 to 5.8 years,
respectively, and median survival conditional to survival at
1 year after transplant improving from 7.2 to 8.7 years,
respectively (Figure 18). Donor age for recipients aged 11 to
17 years did not appear to be associated with death after
transplant (Figure 19).
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Figure 13 Kaplan-Meier survival by recipient age group (lung
transplants: January 1990–June 2011).
0
25
50
75
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Su
rv
iv
al
 (%
)
Years
Single Lung (N=94)
Bilateral/Double Lung  (N=1,553)
Median survival (years): Single Lung = 1.9; Bilateral/Double Lung = 5.4
p < 0.0001
Figure 14 Kaplan-Meier survival by procedure type (pediatric
lung transplants: January 1990–June 2011).
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Figure 15 Kaplan-Meier survival by diagnosis (pediatric lung
transplants: January 1990–June 2011).
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Figure 16 Kaplan-Meier survival by recipient age group (pediatric
lung transplants: January 1990–June 2011).
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Figure 17 Conditional Kaplan-Meier survival by recipient age
group (pediatric lung transplants: January 1990–June 2011).
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Figure 18 Kaplan-Meier survival by era (pediatric lung
transplants: January 1988–June 2011).
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Figure 19 Kaplan-Meier survival by donor age for recipients
aged 11–17 years (pediatric lung transplants: January 1990–June
2011).
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Figure 20 Number of pediatric lung retransplants (retransplants:
January 1994–June 2012).
Benden et al. ISHLT 16th Pediatric Lung and Heart-Lung Transplant Report 993
1 Year  (N=338) 2 Years  (N=279) 3 Years  (N=216)
0%
20%
40%
60%
80%
100%
Figure 24 Functional status of surviving recipients (follow-
ups: March 2005–June 2012).
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Figure 25 Recipient age and hazard ratio of mortality/graft
failure 1 year after transplant (pediatric lung transplants: April
1994–June 2011). Dashed lines indicate the 95% confidence
interval.
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Figure 21 Kaplan-Meier survival by transplant type (pediatric
lung transplants. January 1994–June 2011).
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Figure 22 Survival by time between primary transplant and
retransplant (pediatric lung transplants: January 1988–June 2011).
The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013994Retransplants
A total of 118 lung retransplants performed between
January 1994 and June 2012 were reported to the Registry,
23% of which were undertaken o 12 months after the
primary transplant procedure (time between previous and
current transplant was not reported in 23%; Figure 20).
Overall, survival was significantly inferior when primary
transplant was compared with retransplant (58% vs 45% at
3 years, respectively; p ¼ 0.026; Figure 21). However, a
trend was noted (p ¼ 0.1227) for better outcome for lung0
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Figure 23 Survival by diagnosis (pediatric lung retransplants:
January 1988–June 2011).retransplants in a small group of 100 children if procedures
were performed Z 1 year after the primary transplant (1-
year survival was 62% vs 39%, respectively; Figure 22).
Survival after retransplant for the different indications of
non-obliterative bronchiolitis vs obliterative bronchiolitis
was similar (Figure 23).Functional status
Physician-reported overall functional status of pediatric lung
transplant recipients was good. More than 80% of surviving0.0
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Figure 26 Recipient age and hazard ratio of mortality/graft
failure 5 years after transplant (pediatric lung transplants: April
1994–June 2007). Dashed lines indicate the 95% confidence
interval.
Table 2 Risk Factors for 1-Year Mortality and Graft Failure (Pediatric Lung Transplants: April 1994–June 2011)
Variable No. HR (95% CI) p-value
On ventilator 141 3.13 (2.03–4.81) o 0.0001
Year of transplant: May 1994–2001 vs 2002–June 2011 330 1.82 (1.30–2.53) 0.0004
Donor CMVþ/recipient CMV– 261 1.49 (1.09–2.06) 0.0135
Chronic steroid use 309 1.41 (1.02–1.96) 0.0391
Borderline
Recipient age 0.0620
Pediatric transplant center volume 0.0716
Bilirubin 0.0924
CI, confidence interval; CMV, cytomegalovirus; HR, hazard ratio.
Table 3 Risk Factors for 5-Year Mortality and Graft Failure (Pediatric Lung Transplants: April 1994–June 2007)
Variable No. HR (95% CI) p-value
On ventilator 97 1.92 (1.29–2.87) 0.0014
Year of transplant: April 1994–2001 vs 2002–June 2007 330 1.37 (1.08–1.73) 0.0095
Chronic steroid use 234 1.32 (1.06–1.66) 0.0151
Recipient age 0.0079
Pediatric transplant center volume 0.0022
Height difference 0.0075
CI, confidence interval; HR, hazard ratio.
Benden et al. ISHLT 16th Pediatric Lung and Heart-Lung Transplant Report 995recipients followed up between March 2005 and June 2012 had
a functional status of Z 80% on the Lansky score, as
documented at 1 and at 3 years after transplantation (Figure 24).
Complications and morbidities
Significant risk factors for the combined outcome of death
or graft failure within 1 and 5 years in pediatric patients
were pre-transplant ventilator use, older transplant era, and
chronic steroid use (Tables 2, 3). Further, a trend for an
increased risk of 1-year mortality or graft failure in
recipients who received transplants during adolescent age
(Figure 25) became significant at 5 years (Figure 26). The
most common morbidity in survivors at 1 year after
transplant was hypertension in4 40% of patients, followedTable 4 Cumulative Morbidity Rates in Pediatric Lung
Transplant Survivors Within 1Year Post-transplant (Follow-ups:
April 1994–June 2012)
Within 1 Total with known
Outcome year (%) response (No.)
Hypertension 41.7 701
Renal dysfunction 9.5 723
Abnormal creatinine
o 2.5 mg/dl
6.6
Creatinine 4 2.5 mg/dl 1.9
Chronic dialysis 0.7
Renal transplant 0.3
Hyperlipidemia 5.1 720
Diabetes 23.3 724
Bronchiolitis obliterans syndrome 12.8 674by diabetes mellitus in 23% (Table 4). Within 5 years post-
transplant, hypertension had developed in almost 70% of
survivors followed up between April 1994 and June 2012
(Table 5). Further, chronic kidney disease and diabetes
mellitus were also frequent morbidities in survivors within
5 years post-transplant. The incidence of renal dysfunction
within 5 years after transplantation was 32% in survivors
followed up between April 1994 and June 2012, and 3% of
survivors required dialysis or a renal transplant (Table 5).
Details regarding malignancies after lung transplantation in
children were discussed in last year’s report.1Bronchiolitis obliterans syndrome
Bronchiolitis obliterans syndrome (BOS), the most common
form of chronic lung allograft dysfunction (CLAD), was oneTable 5 Cumulative Morbidity Rates in Pediatric Lung
Transplant Survivors Within 5 Years Post-transplant (Follow-
ups: April 1994–June 2012)
Within 5 Total with known
Outcome years (%) response (No.)
Hypertension 69.1 194
Renal dysfunction 31.7 205
Abnormal creatinineo 2.5 mg/dl 23.9 …
Creatinine 4 2.5 mg/dl 4.9 …
Chronic dialysis 1.5 …
Renal transplant 1.5 …
Hyperlipidemia 17.2 198
Diabetes 36.2 207
Bronchiolitis obliterans syndrome 34.6 159
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Figure 27 Freedom from bronchiolitis obliterans syndrome in
pediatric lung transplant recipients (follow-ups: April 1994–June 2012).
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8
%
 F
re
e 
fr
om
 B
ro
nc
hi
ol
iti
s
O
bl
ite
ra
ns
 S
yn
dr
om
e
Years
<1 year        (N=58)
1-5 Years     (N=72)
6-10 Years   (N=115)
11-17 years (N=433)
No pair-wise comparisons were significant at p < 0.05
Figure 28 Freedom from bronchiolitis obliterans syndrome by
age group (follow-ups: April 1994–June 2012).
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Figure 29 Freedom from bronchiolitis obliterans syndrome by
induction use (follow-ups: April 1994–June 2012).
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Figure 30 Freedom from bronchiolitis obliterans syndrome in
pediatric lung recipients by diagnosis (follow-ups: April 1994–
June 2012). IPAH, idiopathic pulmonary arterial hypertension.
The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013996of the most frequent overall causes of morbidity. BOS was
prevalent in 4 50% of surviving transplant recipients by
5 years post-transplant (Figure 27). Numerically, freedom
from BOS was more common in younger recipients aged
r 5 years than in older children aged Z 11 years, but
this difference did not achieve statistical significance
(Figure 28). No difference in freedom from BOS was found
if recipients were stratified according to induction vs no
induction use (Figure 29). There was also a trend for lower
freedom from BOS in recipients who received transplants for
CF, the most common diagnosis in older children, comparedTable 6 Cause of Death in Pediatric Lung Recipients (Deaths: Janua
0–30 days 31 days–1 ye
(n ¼ 123) (n ¼ 171)
Cause of death No. (%) No. (%)
Bronchiolitis … 17 (9.9)
Acute rejection 3 (2.4) 4 (2.3)
Lymphoma … 8 (4.7)
Malignancy, non-lymphoma … 2 (1.2)
CMV … 6 (3.5)
Infection, non-CMV 16 (13.0) 56 (32.7)
Graft failure 36 (29.3) 33 (19.3)
Cardiovascular 19 (15.4) 7 (4.1)
Technical 14 (11.4) 5 (2.9)
Multiple organ failure 13 (10.6) 21 (12.3)
Other 22 (17.9) 12 (7.0)
CMV, cytomegalovirus.with recipients who received transplants for IPAH, at 45% vs
58% at 5 years, respectively (p ¼ 0.0684; Figure 30).
Cause of death
As in previous reports, graft failure was the most common
cause of death within the first 30 days post-transplant,
occurring in almost 30% of recipients (Table 6). In the first
year after transplantation, non-cytomegalovirus infection
was the cause of death in 24% of pediatric lung transplant
recipients. Beyond 1 year after transplantation, BOS was byry 1992–June 2012)
ar 41–3 years 43–5 years 45 years
(n ¼ 225) (n ¼ 104) (n ¼ 97)
No. (%) No. (%) No. (%)
85 (37.8) 40 (38.5) 46 (47.4)
2 (0.9) 2 (1.9)
7 (3.1) 4 (3.8) 5 (5.2)
1 (0.4) … 3 (3.1)
… … …
35 (15.6) 19 (18.3) 9 (9.3)
55 (24.4) 22 (21.2) 19 (19.6)
3 (1.3) 1 (1.0) 1 (1.0)
6 (2.7) 3 (2.9) 1 (1.0)
11 (4.9) 4 (3.8) 5 (5.2)
20 (8.9) 9 (8.7) 8 (8.2)
Benden et al. ISHLT 16th Pediatric Lung and Heart-Lung Transplant Report 997far the leading cause of death recorded in recipients between
January 1992 and June 2012, and this figure increased from
38% deaths at 1 to 5 years after transplantation to 47% of
deaths beyond 5 years after transplantation (Table 6).
Conclusions
More than 2,000 pediatric lung and heart-lung transplants
have been reported to the ISHLT Registry to date, the
largest data collection of its kind in the field of pediatric
lung transplantation; hence, it is an important data source to
illustrate the increasing pediatric lung transplant activity
worldwide and its overall outcomes and complications. The
2013 ISHLT Registry report on pediatric lung trans-
plantation documents an improved overall survival after
lung transplantation in children and adolescents and results
that compare well with adult lung transplantation. However,
BOS, the most common form of CLAD, remains the
Achilles heel, preventing better long-term outcomes, and is
the overall leading cause of why long-term survival afterpediatric lung transplantation is lower compared with
pediatric heart transplantation or other solid-organ trans-
plantation in children.
Disclosure statement
All relevant disclosures for the Registry Director, Executive
Committee Members, and authors are on file with the ISHLT and
can be made available for review by contacting the Executive
Director of the ISHLT.
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